Immediate Impact

8 from Science/Nature 63 standout
Sub-graph 1 of 24

Citing Papers

Glioblastoma Therapy: Past, Present and Future
2024 Standout
Late-stage Functionalization for Improving Drug-like Molecular Properties
2023 Standout
1 intermediate paper

Works of Alex McCormick being referenced

Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial
2020
Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca.
2001

Author Peers

Author Last Decade Papers Cites
Alex McCormick 281 94 255 218 17 735
S. Unger 251 138 134 179 19 708
Georgina Meneses‐Lorente 259 119 339 107 51 837
Helen Ambrose 217 86 143 230 21 597
Katrijn Bogman 313 130 191 98 18 715
Shazia Ali 212 163 251 201 14 738
Raju D. Amin 106 165 125 259 15 783
Suman Lal 263 157 184 203 25 841
Iwao Yamada 212 92 228 131 17 668
P. Kellie Turner 370 55 156 123 43 787
Maureen Boxer 100 113 240 108 14 616

All Works

Loading papers...

Rankless by CCL
2026